Home   >    COVID-19   >   Covid-19 Proteins

2019-nCoV NSP10/NSP16 Methyltransferase, Active

Recombinant 2019-nCoV NSP10/NSP16 methyltransferase includes full length NSP10 (A4254-Q4392) and NSP16 (S6799-N7096) expressed in E. coli using C-terminal His tag.


10 ug 20 ug 50 ug

$ 226


Many eukaryotic viruses have evolved 2′-O-methyltransferases (2′-O-MTase) to modify their viral mRNAs and carry a cap-1 structure (m7GpppNm) at the 5′ end. This 5’ cap structure is important for viral mRNA stability, protein translation and viral immune escape (1). SARS-CoV possess NSP16 that has 2′-O-MTase activity. NSP16 requires NSP 10 for activation which is a conserved mechanism in corona viruses (2). Therefore, inhibitors targeting the NSP10/NSP16 2′-O-MTase are potential targets for developing anti-coronavirus drugs (3).

Gene Aliases:

NSP10: Non-structural protein 10
NSP16: Non-structural protein 16

Genebank Number:


50mM sodium phosphate, pH 7.0, 300mM NaCl, 150mM imidazole, 0.25mM DTT, 25% glycerol.


1. Furuichi, Y. et al: Viral and cellular mRNA capping: past and prospects. Adv Virus Res. 2000, 55:135–184.

2. Decroly, E. et al. Coronavirus nonstructural protein 16 is a cap-o binding enzyme possessing (nucleoside-2'O)-methyltransferase activity. J Virol. 2008, 82(16):8071-8084.

3. Chen, Y. et al: Biochemical and structural insights into the mechanisms of SARS coronavirus RNA ribose 2’-O-methylation by nsp16/nsp10 protein complex. PLoS Pathog. 2011, 7(10): e1002294.

There are no related publications available for this product.


Acute Respiratory Distress Syndrome , Cardiovascular Disease, Cell Cycle, Cellular Stress, COVID19, Gastrointestinal Diseases , Infectious Diseases , Inflammation, Lung Diseases , Neurobiology, severe acute respiratory syndrome coronavirus 2 , Virology